GB9323162D0 - 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf - Google Patents

4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf

Info

Publication number
GB9323162D0
GB9323162D0 GB939323162A GB9323162A GB9323162D0 GB 9323162 D0 GB9323162 D0 GB 9323162D0 GB 939323162 A GB939323162 A GB 939323162A GB 9323162 A GB9323162 A GB 9323162A GB 9323162 D0 GB9323162 D0 GB 9323162D0
Authority
GB
United Kingdom
Prior art keywords
phenylsulphonamid
methylimidazo
pyridinylmethyl
paf
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939323162A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Bio Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology Ltd filed Critical British Bio Technology Ltd
Priority to GB939323162A priority Critical patent/GB9323162D0/en
Publication of GB9323162D0 publication Critical patent/GB9323162D0/en
Priority to PCT/GB1994/002460 priority patent/WO1995013064A1/en
Priority to JP7513680A priority patent/JPH09505040A/en
Priority to AU81125/94A priority patent/AU8112594A/en
Priority to CA002176124A priority patent/CA2176124A1/en
Priority to GB9606996A priority patent/GB2298138B/en
Priority to EP95900227A priority patent/EP0727995A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
GB939323162A 1993-11-10 1993-11-10 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf Pending GB9323162D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB939323162A GB9323162D0 (en) 1993-11-10 1993-11-10 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf
PCT/GB1994/002460 WO1995013064A1 (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
JP7513680A JPH09505040A (en) 1993-11-10 1994-11-09 4- (1H-2-methylimidazo4.5-C pyridinylmethyl) -phenylsulfonamide carboxylic acid derivative as antagonist
AU81125/94A AU8112594A (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
CA002176124A CA2176124A1 (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
GB9606996A GB2298138B (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
EP95900227A EP0727995A1 (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939323162A GB9323162D0 (en) 1993-11-10 1993-11-10 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf

Publications (1)

Publication Number Publication Date
GB9323162D0 true GB9323162D0 (en) 1994-01-05

Family

ID=10744942

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939323162A Pending GB9323162D0 (en) 1993-11-10 1993-11-10 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf

Country Status (6)

Country Link
EP (1) EP0727995A1 (en)
JP (1) JPH09505040A (en)
AU (1) AU8112594A (en)
CA (1) CA2176124A1 (en)
GB (1) GB9323162D0 (en)
WO (1) WO1995013064A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508748D0 (en) * 1995-04-28 1995-06-14 British Biotech Pharm Benzimidazole derivatives
JP3628335B2 (en) 1996-01-23 2005-03-09 塩野義製薬株式会社 Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
ATE233552T1 (en) * 1996-07-22 2003-03-15 Monsanto Co THIOL-SULFONES AS METALLOPROTEINASE INHIBITORS
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE70217B1 (en) * 1990-08-15 1996-10-30 British Bio Technology Benzimidazole derivatives process for their preparation and application

Also Published As

Publication number Publication date
JPH09505040A (en) 1997-05-20
CA2176124A1 (en) 1995-05-18
EP0727995A1 (en) 1996-08-28
WO1995013064A1 (en) 1995-05-18
AU8112594A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
PL331431A1 (en) Fluorine containing 1,4-substituted derivatives of piperidine
HU9302460D0 (en) 5/20/4-(1,2-benzisothiazole-3-yl)-1-pierazinyl/ethyl/-6-chlorine-1,3-dihydro-2h-indole-2-one-hydrogen-chloride-mononhydrate
AU5704894A (en) Phenyl derivatives useful as tachykinin antagonists
PL309975A1 (en) Derivatives of 2,6-diaminopurine
EP0414491A3 (en) 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
GB9208492D0 (en) Heterocyclic compounds
EP0533242A3 (en) Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
EG20279A (en) New derivatives of 3 arylpyrazoles used as fungicides
AU4261293A (en) 1-piperazineacetic derivatives as fibrinogen receptor antagonists
AU3256193A (en) 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents
GB9219634D0 (en) Heterocyclic compounds
AU2759892A (en) N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
AU5455194A (en) Substituted phthalazinones as nerotensin antagonists
EP0414490A3 (en) 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-one as 5 alpha-reductase inhibitors
GB9323162D0 (en) 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf
EP0708765A4 (en) Substituted piperazinylcamphor derivatives as oxytocin antagonists
GB9215361D0 (en) Heterocyclic compounds
EP0662964A1 (en) Heterocyclic amines having colmodulin antagonist properties.
GB2264115B (en) 1H-2-Methylimidazo(4,5-c)pyridinyl Derivatives as PAF Antagonists
HU9300217D0 (en) Heterocyclic compounds
GB9219632D0 (en) Heterocyclic compounds
GB9313201D0 (en) New heterocyclic compounds
KR950700297A (en) 2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist as 5-HT3-receptor antagonist
ZA866273B (en) Substituted 2,3,3a,6-tetrahydro-6-oxobenzofuran derivatives useful as paf antagonists
GR3033237T3 (en) Quinoline derivatives as leukoriene antagonists.